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gust 26, 2013.his study sought to explore molecular mechanisms underlying the adrenergic-induced QT prolongation associated
with KCNQ1 mutations.Background The most frequent type of congenital long QT syndrome is LQT1, which is caused by mutations in the gene (KCNQ1)
that encodes the alpha subunit of the slow component of delayed rectiﬁer Kþ current (IKs) channel. We identiﬁed 11
patients from 4 unrelated families that are heterozygous for KCNQ1-G269S. Most patients remained asymptomatic,
and their resting corrected QT intervals ranged from normal to borderline but were prolonged signiﬁcantly during
exercise.Methods Wild-type (WT) KCNQ1 and/or KCNQ1-G269S (G269S) were expressed in mammalian cells with KCNE1. IKs-like
currents were measured in control conditions or after isoproterenol or protein kinase A (PKA) stimulation using the
patch-clamp technique. Additionally, experiments that incorporated the phosphomimetic KCNQ1 substitution, S27D,
in WT or KCNQ1-G269S were also performed.Results The coexpression of WT-KCNQ1 with varying amounts of G269S decreased IKs, shifted the current-voltage I-V relation
of IKs to more positive potentials, and accelerated the IKs deactivation rates in a concentration-dependent manner.
In addition, the coexpression of G269S and WT blunted the activation of IKs in response to isoproterenol or PKA
stimulation. Lastly, a phosphomimetic substitution in G269S did not show an increased IKs.Conclusions G269S modestly affected IKs in control conditions, but it almost completely blunted IKs responsiveness in conditions
that simulate or mimic PKA phosphorylation of KCNQ1. This insensitivity to PKA stimulation may explain why
patients with G269S mutation showed an excessive prolongation of QT intervals on exercise. (J Am Coll Cardiol
2014;63:819–27) ª 2014 by the American College of Cardiology FoundationCongenital long QT syndrome (LQTS) is characterized by
an abnormal QT interval prolongation on the electrocar-
diogram (ECG), syncope due to a polymorphic ventricular
tachycardia called “torsade de pointes,” and ventricular
ﬁbrillation (1,2). At least 13 genes are responsible for
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; revised manuscript received August 5, 2013,LQT1 being the most common and accounting for
approximately 40% to 50% of genotyped patients (3,4).
LQT1 is caused by mutations in KCNQ1, the alpha subunit
of the slow component of delayed rectiﬁer Kþ current (IKs),
which is a major repolarizing current during the plateau
phase of cardiac action potentials (5).
See page 828
The impaired expressionor dysfunctionof IKs channels (6,7)
can lead to a prolongation in the cardiac action potential and
the QT interval on an ECG (7,8). A major role for IKs is to
maintain the ventricular action potential duration by offsetting
the increase in L-type Ca2þ current (ICa,L) after adrenergic
stimulation. Adrenergic stimulation activates protein kinase A
(PKA), which directly increases IKs by phosphorylating the
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820LQT1 patients experience trig-
gered cardiac events during ad-
renergic stimulation (i.e., while
exercising) (9,10).
More recently, we identiﬁed
a heterozygous missense KCNQ1
mutation, G269S, in 11 patients
from 4 unrelated families. Similar
toprevious clinical reports (10–12),
most of our patients have nor-
mal to borderline corrected QT
(QTc) intervals at rest, but their
QTc intervals are signiﬁcantly
prolonged after exercise. We
characterize the functional con-
sequences of the IKs channel
reconstituted with G269S in
mammalian cells and provide
important insight into molecu-
lar mechanisms underlying the
adrenergic-induced LQTS. Spe-
ciﬁcally, we found G269S mod-
estly affected IKs but severely
blunted the increase in IKs with
isoproterenol, pharmacologicalactivators of PKA, and with the PKA phosphomimetic
mutation KCNQ1-S27D. These ﬁndings may explain why
patients with G269S mutation showed an excessive
prolongation of QT intervals on exercise and suggest
a potential beneﬁt of beta-blocker therapy.Methods
Clinical investigation and genetic testing. The clinical
diagnosis of LQTS was referred to the criteria of Schwartz
et al. (2). The protocol for genetic analysis was approved by
the institutional ethics committee and performed under its
guidelines. Written informed consent was obtained from
every subject before the analysis. Genomic deoxyribonucleic
acid (DNA) used for genetic evaluation was isolated from
venous blood lymphocytes. In addition to KCNQ1, genetic
screening for mutations in other LQTS-related genes
including SCN5A, KCNH2, KCNE1, KCNE2, and KCNJ2
was conducted by denaturing high-performance liquid chro-
matography (WAVE system, Transgenomic Inc., Omaha,
Nebraska). For abnormal screening patterns, sequencing
was performed with an automated sequencer (ABI PRISM
3100x, Applied Biosystems, Foster City, California).
Heterologous expression of cDNA in CHO and HEK293
cells. Full-length complementary deoxyribonucleic acid
(cDNA) encoding human wild-type (WT) KCNQ1 (Gen-
Bank AF000571, Institut de Pharmacologie Moleculaire et
Cellulaire, CNRS, Valbonne, France) was subcloned into
a pIRES2-EGFP expression vector. KCNQ1-G269S,
KCNQ1-S27D, and KCNQ1-(S27D-G269S) mutants were
constructed using a Quick Change II XL site-directedmutagenesis kit (Stratagene, La Jolla, California), and they
were also subcloned into the pIRES2-EGFP expression
vector. Full-length cDNA encoding human KCNE1
(GenBank M26685) subcloned into the pCDNA3.1
expression vector was obtained by polymerase chain reaction
from human heart cDNA library (Clontech, Mountain
View, California). Full-length cDNA encoding human A-
kinase-anchoring protein 9 (Yotiao or AKAP9) was subcl-
oned into pCDNA3.1 expression vector (Department of
Bio-Informational Pharmacology, Tokyo Medical and
Dental University, Japan). KCNQ1-WT and/or its mutants,
KCNE1 and Yotiao cDNA were transiently transfected into
Chinese hamster ovary (CHO) or human embryonic kidney
293 (HEK293) cells using Lipofectamine (Invitrogen Life
Technologies Inc., Carlsbad, California) according to the
manufacturer’s instructions.
Solutions and chemicals. The pipette solution contained (in
mmol/l) 70 potassium aspartate, 40 KCl, 10 KH2PO4, 1
MgSO4, 3 Na2 adenosine triphosphate (Sigma, St. Louis,
Missouri), 0.1 Li2 Guanosine-5’-triphosphate (Roche Diag-
nostics GmbH, Mannheim, Germany), 5 ethylene glycol
tetraacetic acid, and 5 N-2-hydroxyethylpiperazine-N-2-
ethanesulfonic acid; and the pH was adjusted to 7.2 with
KOH. The extracellular solution contained (in mmol/l) 140
NaCl, 5.4 KCl, 1.8 CaCl2, 0.5 MgCl2, 0.33 NaH2PO4,
5.5 glucose, and 5.0 N-2-hydroxyethylpiperazine-N-2-
ethanesulfonic acid; the pH was adjusted to 7.4 with NaOH.
Isoproterenol (Sigma) was dissolved in distilled water (con-
taining 1 mmol/l ascorbic acid) to yield 10 mmol/l stock
solution andkept in the dark at 4C.Forskolin (FK,Sigma) and
3-isobutyl-l-methyl-xanthine (IBMX, Sigma) were respec-
tively dissolved in dimethyl sulfoxide (Sigma) to yield stock
solutions of 5 mmol/l and 15 mmol/l, respectively.
Electrophysiological recordings and data analysis. Forty-
eight hours after transfection, cells attached to a glass coverslip
were transferred to a 0.5-ml bath chamber perfused with
extracellular solution and maintained at 25C. Patch-clamp
experiments were conducted on green ﬂuorescent protein-
positive cells. Whole-cell membrane currents were recorded
with an EPC-8 patch-clamp ampliﬁer (HEKA, Lambrecht,
Germany). IKs were evoked by depolarizing voltage-clamp
steps given from a holding potential of –80 mV to various
test potentials. IKs amplitude was determined by measuring
the amplitude of tail current elicited on repolarization to –50
mV following 2-s depolarization to 30 mV every 10 s, and
currents were normalized to the cell membrane capacitance to
obtain current densities (pA/pF). Voltage-dependence of IKs
activation was evaluated by ﬁtting the I-V relation of the tail
currents to a Boltzmann equation: IK,tail ¼ 1/[1þexp([Vh –
Vm]/k)], where IK,tail is the tail current amplitude density,Vh is
the voltage at half-maximal activation,Vm is the test potential,
and k is the slope factor. The deactivation kinetics of IKs after
depolarization was determined by a single exponential ﬁt of
tail current trace.
Immunocytochemistry. Forty-eight hours after trans-
fection, CHO cells were ﬁxed with 3.7% formaldehyde in
Figure 1 Molecular Discovery and Clinical Characterization of KCNQ1-G269S
(A) Four pedigrees of patients carrying the G269S mutation. Solid symbols indicate mutation carriers, arrows probands, and symptomatic patient (S). Square and circle
symbols represent male and female subjects. (B) Predicted topology of IKs channel. Red asterisk indicates the location of G269S mutation. (C) A representative result of
deoxyribonucleic acid sequence analysis: upper trace, control and lower, the proband in Family #2. Red arrows indicate the location of heterozygous mutation. (D) Twelve-lead
electrocardiograms (left: resting and right: after exercise) in a 7-year-old (y.o.) boy from Family #2 (bold arrow). QTc ¼ corrected QT interval.
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821phosphate-buffered saline (PBS) for 10 min at room
temperature, rinsed once in PBS, and permeabilized with
0.2% triton X-100 in PBS. Cells were blocked with 5%
bovine serum albumin in PBS for 30 min and then incubated
overnight at 4C with anti-Kv7.1 (KCNQ1, Santa Cruz
Biotechnology, Inc., Santa Cruz, California) antibody against
its C-terminus at 1:2,000 dilution. Following incubation,
cells were labeled with AlexaFluor 488-conjugated goat
antirabbit immunoglobulin G (Molecular Probes, Eugene,
Oregon) at 1:500 dilution. Immunoﬂuorescence stained cells
were captured using a confocal laser scanning microscope
(LSM META 510, Carl Zeiss, Berlin, Germany).
All data are expressed as mean SE (QTc as mean SD),
with the number of experiments in parentheses. Statistical
comparisons were analyzed using unpaired Student t test and
1-way or 2-way analysis of variance with Newman-Keuls
post hoc test. A p value of <0.05 was considered statistically
signiﬁcant.Results
Case description. Genotype analyses of 551 consecutive
LQTS probands identiﬁed 4 unrelated carriers with the
KCNQ1-G269S mutation. Figure 1A shows 4 familypedigrees for the different probands (arrows). Figure 1B
shows the location of the mutation (transmembrane domain
S5) in the KCNQ1 alpha subunit, and the lower panel in
Figure 1C shows representative results of a genotype-
positive patient’s sequencing data (805G>A).
Figure 1D depicts 2 sets of 12-lead ECG recorded from
a 7-year-old boy in Family #2 (Fig. 1A, bold arrow). His
resting QTc interval was 437 ms, but it was prolonged to
494 ms after exercise. The boy was asymptomatic, but his
maternal grandfather died suddenly at the age of 28 years
(the detailed clinical information is not available). In
Family #4, the 22-year-old female proband experienced
sudden syncope, which recovered soon and was suspected
to be due to ventricular tachyarrhythmia, while dancing,
but her symptoms have disappeared after receiving beta-
adrenergic blocker metoprolol tartrate for 42 months.
We performed an exercise tolerance test in 8 of the 11
mutation carriers (Fig. 1A). The mean resting QTc intervals
were 441.6  44.5 ms but signiﬁcantly (p < 0.05) prolonged
to 485.5  14.4 ms after exercise. Therefore, KCNQ1-
G269S might minimally affect IKs at rest but impair the up-
regulation of IKs by PKA, because the exercise stress (PKA
activation) does not prolong the QTc interval in control
subjects (13).
Figure 2 G269S Decreases IKs in a Mutant Concentration-Dependent Manner
Representative current traces recorded from Chinese hamster ovary cells expressing 0.5 mg KCNE1 with 0.5 mg KCNQ1-WT (A), 0.5 mg KCNQ1-WT þ 0.25 mg KCNQ1-G269S
(B), 0.5 mg KCNQ1-WT þ 0.5 mg KCNQ1-G269S (C), and 0.5 mg KCNQ1-G269S (D). The slow component of delayed rectiﬁer Kþ current (IKs) was activated by depolarizing
voltage-clamp steps (inset in A) given from a holding potential of –80 mV to potentials between –50 and þ50 mV in 10-mV increments for 2 s. Dashed line indicates zero current
level. (E) Current-voltage (I-V) relations for tail IKs elicited after the voltage-step to –50 mV from various test potentials. (F) Bar graphs showing the mean peak tail IKs densities
recorded on repolarization to –50 mV following 2-s depolarization to 30 mV for the different transfection conditions. **p < 0.01 versus KCNQ1-WT. WT ¼ wild type.
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822KCNQ1-G269S mutation causes a mild loss-of-function
in IKs in control conditions. Figures 2A to 2D show 4
sets of representative current traces recorded from CHO
cells expressing KCNE1 with KCNQ1-WT, KCNQ1-
WT þ KCNQ1-G269S, and KCNQ1-G269S, respectively.
Cells transfected with varying amounts of G269S cDNA
reduced both the steady state and tail IKs amplitudes in
a concentration-dependent manner.
Figure 2E shows the current-voltage (I-V) relations for tail
IKs elicited after the voltage-step to –50 mV from various test
potentials, and Figure 2F summarizes tail IKs densities under
4 different conditions. Compared with WT, G269S alone or
WT þ G269S signiﬁcantly decreased the mean IKs density
for voltages between –20 mV and 50 mV and the mutation
displayed a moderate dominant-negative suppression on
WT-KCNQ1 function.Figure 3A shows the normalized I-V relations for tail
IKs in Figure 2E. The individual I-V relations were described
by the Boltzmann equation to calculate the voltage for
half-maximal activation (Vh) and slope factor (k) values
(Table 1). Coexpressing WT with different amounts of
G269S increased the Vh and k in a concentration-dependent
manner.
Deactivation rates for IKs were measured by depolarizing
cells to 30 mV for 2 s, followed by a tail-pulse from –60 mV
to –30 mV in 10-mV increments. Figure 3B shows the time
constant for deactivation plotted as a function of tail-pulse
potential. Compared with WT, G269S signiﬁcantly accel-
erated the deactivation rates between –60 mV and –30 mV.
In addition, coexpressing WT with increasing amounts of
G269S showed a concentration-dependent acceleration of
IKs deactivation kinetics.
Figure 3 G269S Affects the Activation Gate of IKs Channels
(A) The normalized I-V relation of peak tail IKs recorded from Chinese hamster ovary cells expressing 0.5 mg KCNE1 with 0.5 mg KCNQ1-WT (open circles), 0.5 mg KCNQ1-WT þ
0.25 mg KCNQ1-G269S (open squares), 0.5 mg KCNQ1-WT þ 0.5 mg KCNQ1-G269S (open triangles), and 0.5 mg KCNQ1-G269S (solid circles). (B) Deactivation time constants
(s) obtained by ﬁtting the tail IKs decay (inset) to a single exponential function for voltages between –60 mV and –30 mV. *p < 0.05 and **p < 0.01 versus KCNQ1-WT.
Abbreviations as in Figure 2.
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823Effects of G269S mutant subunits on the expression of
KCNQ1 tetramers. Figure 4 shows microscopic phase
contrast (Fig. 4A) and confocal images (Fig. 4B) of 3 CHO
cells expressing KCNE1 with KCNQ1-WT, WT þ G269S
mutation, and G269S alone. KCNQ1-WT proteins were
amply transported to the cell membrane. In cells expressing
G269S alone, G269S proteins were mostly distributed in
the cytosol. In cells expressing WT þ G269S, WT þ
G269S proteins were expressed both on the cell membrane
and in the cytosol, suggesting that the cell membrane
expression of channel proteins is increased by the coex-
pression of WT subunits.
IKs reconstituted with G269S mutant reduces its
responses to PKA stimulation. To explain how G269S
may be causing adrenergic-induced prolongation of QTc
intervals, we tested whether G269S might impair the PKA-
mediated regulation of IKs in HEK293 cells expressing
KCNQ1-WTand/orG269SwithKCNE1 andYotiao protein
(8) (we failed to record the response of IKs to beta-adrenergic
agonist isoproterenol or PKA stimulation in CHO cells).
In cells expressing WT, both isoproterenol (100 nmol/l)
(Fig. 5A) and a PKA-stimulating cocktail (5 mmol/l FKþ 15Table 1
KCNQ1-G269S Affects the Activation Gate of
IKs Channels
n Vh (mV) k (mV)
0.50 mg WT 15 2.4  1.7 13.2  0.4
0.50 mg WT þ 0.25 mg G269S 13 8.9  3.3* 15.2  0.4*
0.50 mg WT þ 0.50 mg G269S 11 25.4  5.2* 17.8  0.8*
0.50 mg G269S 13 68.3  8.3* 23.4  1.8*
Values are mean  SD. *p < 0.01 versus WT.
IKs ¼ slow component of delayed rectiﬁer Kþ current; WT ¼ wild type.mmol/l IBMX) (Fig. 5B) increased tail IKs density byw100%.
In contrast, cells expressing G269S or WT þ G269S
dramatically reduced the response of the peak tail IKs to
isoproterenol or the PKA stimulation. Figure 5C shows the
bar graphs that summarize the percent increase in tail IKs
densities. These data suggest thatG269Sblunted the response
of IKs to beta-adrenergic agonist or PKA stimulation.
G269S prevents the increase in IKs caused by the phos-
phomimetic S27D mutation. To elucidate further the
mechanism underlying the attenuation of this PKA-
mediated phosphorylation by G269S mutation, we engi-
neered the phosphomimetic KCNQ1-S27D mutation with
or without G269S mutation (14) and examined IKs reca-
pitulated by coexpressing KCNE1 and Yotiao (Fig. 6).
Compared with WT, S27D increased IKs amplitudes
considerably (Figs. 6A and 6B), which is similar to what was
reported previously (14,15). Figure 6C shows that, consis-
tent with S27D mimicking a PKA phosphorylated IKs
channel, the application of 100 nmol/l of isoproterenol only
slightly affected the peak tail IKs (14.1  5.5%, n ¼ 7). In
contrast, compared with G269S, S27D-G269S did not
increase peak tail IKs (Figs. 6D and 6E). The data are
summarized in Figure 6F. Therefore, G269S prevents PKA
up-regulation of IKs even if S27 is phosphorylated.Discussion
The present study revealed that G269S causes adrenergic-
induced LQT, exerts a moderate dominant-negative
suppression on the IKs channel, and prevents up-regulation
in response to PKA stimulation. The exercise-dependent
unmasking of QTc prolongation observed in our G269S
Figure 4 Cellular Localization of KCNQ1 Proteins in CHO Cells
Microscopic phase contrast images (A) and corresponding confocal images (B) are shown of representative Chinese hamster ovary (CHO) cells coexpressing 0.5 mg KCNE1 and
0.5 mg KCNQ1-WT (upper), 0.5 mg KCNQ1-WT þ 0.5 mg KCNQ1-G269S (middle), or 0.5 mg KCNQ1-G269S (lower). The cells were immunostained with an anti-KCNQ1 antibody.
WT ¼ wild type.
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824patients is likely due to an adrenergic up-regulation of ICa,L
without concomitant up-regulation of IKs.
Approximately 20% to 25% of genotype-conﬁrmed
LQTS patients have a normal range of QTc (16,17)
and the percentage of these silent mutation carriers is
signiﬁcantly higher in LQT1 (36%) than in the other 2
major types of LQTS (LQT2, 19%, and LQT3, 10%).
Lethal arrhythmias can occur in these apparently healthy
silent mutation carriers without any premonitory sign (4,18).
Several cases of physical-exertion–triggered cardiac events
(including death) have been reported in silent G269S
carriers (10–12).
Mutations in KCNQ1 are responsible for defects in IKs,
which is the main outward component in maintaining
cardiac repolarization reserve and highly sensitive to cate-
cholamines (5,19). Functional analysis showed that G269S
mutation reduced IKs density independent of changes in
gating, shifted the I-V relation to a more depolarizing
direction, and accelerated the deactivation time course.
Taken together, G269S mutation exerted “loss-of-function”
effects on the IKs channel.Immunocytochemical studies (Fig. 4) indicated that
G269S decreased cell surface expression of channel proteins.
However, the trafﬁcking-deﬁciency was partially rescued by
coexpression of the WT subunits, resulting in the increased
expression of channel proteins on the cell membrane. In
contrast to the trafﬁcking-deﬁcient LQT1 mutations
KCNQ1-DS276 and T587M (7,20), G269S appeared to
form heteromultimers with WT and trafﬁc to the cell
membrane. We suspect that the partial correction of the
G269S trafﬁcking-deﬁcient phenotype by coexpression with
WT might partially explain why the clinical phenotype of
KCNQ1-G269S mutation carriers is mild despite the
observation that the channels are functionally defective.
In human ventricular myocytes, the rapid component of
delayed rectiﬁer Kþ current, IKr, and ICa,L normally play the
dominant role in regulating the ventricular action potential
at rest (21,22). Therefore, KCNQ1 mutations (e.g., G269S)
that cause a mild-to-moderate functional defect in IKs might
ordinarily have little effect on the ventricular action poten-
tial. In contrast, IKs plays a major role in regulating the
ventricular action potential after adrenergic stimulation,
Figure 5 IKs Reconstituted With KCNQ1-G269S Reduced Responses to PKA Stimulation
Superimposition of IKs traces recorded from human embryonic kidney 293 cells expressing 2 mg Yotiao þ 0.5 mg KCNE1 with 0.5 mg KCNQ1-WT, 0.5 mg KCNQ1-WT þ 0.5 mg
KCNQ1-G269S, and 0.5 mg KCNQ1-G269S before and after bath application of 100 nmol/l isoproterenol (A) or 5 mmol/l forskolin (FK) þ 15 mmol/l 3-isobutyl-l-methyl-xanthine
(IBMX) (B). (C) The percentage increase in tail IKs after bath application of 100 nmol/l isoproterenol (upper) and 5 mmol/l FK þ 15 mmol/l IBMX (lower). **p < 0.01 versus
KCNQ1-WT. PKA ¼ protein kinase A; other abbreviations as in Figure 2.
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825which activates IKs to prevent excessive ventricular action
potential duration or QT prolongation by ICa,L (8,23). The
role that IKs plays during adrenergic stimulation may explain
why 62% of cardiac events in LQT1 patients occur during
exercise (8,9). The blunted response of G269S channels to
both beta-adrenergic agonist and PKA stimulation (Fig. 5)Figure 6 G269S Prevents the Increase in IKs Caused by the Phospho
Representative current traces recorded from human embryonic kidney 293 cells express
exposure to 100 nmol/l isoproterenol (C), 0.5 mg G269S (D), and 0.5 mg S27D-G269S (E)
graphs show effects of G269S on tail IKs densities recorded on repolarization to –50 mV
**p < 0.01 versus KCNQ1-WT. Abbreviations as in Figure 2.may result in excessive ventricular action potential duration
and QTc prolongation speciﬁcally during exercise.
Consistent with previous reports (14,15), our experiments
also demonstrated that the S27D mutant mimicked the
PKA-mediated phosphorylation of IKs channels and
increased IKs (Fig. 6). In contrast, S27D did not mimicmimetic S27D Mutation
ing 2 mg Yotiao þ 0.5 mg KCNE1 with 0.5 mg KCNQ1-WT (A), 0.5 mg S27D (B) and
, respectively. IKs was elicited by the same protocol as that in Figure 2A (inset). (F) Bar
following a 2-s depolarization to 30 mV for the different transfection conditions.
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826PKA phosphorylation of IKs with G269S mutation.
Therefore, G269S appears to prevent the functional effect
that phosphorylation at S27 has on IKs.
Several groups have recently reported that different LQT1
mutations reduce the PKA sensitivity of IKs. Heijman et al.
(15) reported that the A341V, which predisposes patients to
a severe form of LQT1 (24), is also less sensitive to PKA
stimulation. The decreased sensitivity to PKA is because
A341V blunts phosphorylation at S27. Consistent with this,
compared with cells expressing A341V, cells expressing
S27D-A341V mimicked PKA stimulation and caused an
up-regulation in IKs. We show a novel mechanism for PKA
insensitivity. Unlike S27D-A341V, S27D-G269S did not
mimic PKA stimulation of IKs, suggesting that G269S
dissociates the link between phosphorylation at S27 and up-
regulation of IKs.
Additionally, Barsheshet et al. (25) showed that patients
with LQT1 mutations in the cytoplasmic loops between the
S2 and S3 or S4 and S5 have a high risk for life-threatening
events and derive a beneﬁt from treatment with beta-
adrenergic blockers. These mutations generate IKs, which is
also resistant to PKA activation. Our ﬁndings ﬁrst demon-
strated that a “latent” LQT1 mutation could also be insen-
sitive to PKA stimulation, which may explain the unmasking
of the latent LQT1 phenotype that occurs during exercise.
Consistent with the previous ﬁndings (25), the cardiac events
of our symptomatic G269S patient have disappeared since
beginning beta-blocker therapy for 42 months. This suggests
that beta-adrenergic therapy would also be effective in
patients with latent LQT1 mutations such as G269S. We
speculate that beta-blocker therapy is effective because it
would inhibit adrenergic-induced increases in ICa,L, which
would minimize QTc prolongation with exercise.
Study limitations. In the present study, we screened the
mutations that are responsible for LQT1, 2, 3, 5, 6, and 7.
Therefore, the comorbidity of other types of LQTS was not
completely excluded, although their frequency was quite low.
In addition, only one patient was symptomatic of cardiac
event and received beta-adrenergic blocker. Further studies
are required to conﬁrm that beta-blocker therapy may
protect individuals who carry KCNQ1 mutations insensitive
to PKA regulation.
Conclusions
We found that G269S caused moderate functional
dysfunction in control conditions but almost completely
disrupted PKA mediated up-regulation in IKs. This is likely
why the G269S patients have borderline resting QTc
intervals but signiﬁcantly longer QTc while exercising.
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